The DYNAMO Trial: IPI-145 for Refractory Indolent Non-Hodgkin Lymphoma
Julian Adams, PhD, president, Research and Development, Infinity Pharmaceuticals, discusses the rationale for a phase II trial looking at IPI-145 for the treatment of patients with refractory indolent non-Hodgkin lymphoma.
Clinical Pearls
Julian Adams, PhD, president, Research and Development, Infinity Pharmaceuticals, discusses the rationale for a phase II trial looking at IPI-145 for the treatment of patients with refractory indolent non-Hodgkin lymphoma. This trial, labeled DYNAMO, was presented at the 2014 ASCO Annual Meeting.
- In the course of a phase I investigation of IPI-145, patients with indolent lymphoma were enrolled.
- The overall response rate of this group was 73%. The complete response rate was 20%.
- These results were compelling enough to enroll a single-arm study of 120 patients with refractory indolent non-Hodgkin lymphoma. The trial is ongoing.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
